Glaucomas: Neovascular glaucoma

Adam S. Wenick; Alan L. Robin

doi:10.1007/978-3-540-68240-0_49

Glaucomas: Neovascular glaucoma

Adam S. Wenick, Alan L. Robin

School of Medicine

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Topical and oral medical therapies are the initial treatment of choice to lower intraocular pressure (IOP) and limit vision loss and pain secondary to neovascular glaucoma (NVG). Therapies aimed at decreasing aqueous production (beta-blockers, topical and systemic carbonic anhydrase inhibitors, and alpha adrenergics) have the soundest rationale for use in NVG. No study is available in the literature comparing effectiveness of these various medications in NVG, and they are often required in combination. If the IOP is markedly elevated, it would not be inappropriate to commence simultaneously with an alpha-agonist, topical nonselective beta blocker, and topical carbonic anhydrase inhibitor.

Original language	English (US)
Title of host publication	Pearls of Glaucoma Management
Publisher	Springer Berlin Heidelberg
Pages	379-387
Number of pages	9
ISBN (Print)	9783540682387
DOIs	https://doi.org/10.1007/978-3-540-68240-0_49
State	Published - 2010

ASJC Scopus subject areas

General Medicine

Access to Document

10.1007/978-3-540-68240-0_49

Cite this

@inbook{335e6608fd95452ba10760757db68c8d,

title = "Glaucomas: Neovascular glaucoma",

abstract = "Topical and oral medical therapies are the initial treatment of choice to lower intraocular pressure (IOP) and limit vision loss and pain secondary to neovascular glaucoma (NVG). Therapies aimed at decreasing aqueous production (beta-blockers, topical and systemic carbonic anhydrase inhibitors, and alpha adrenergics) have the soundest rationale for use in NVG. No study is available in the literature comparing effectiveness of these various medications in NVG, and they are often required in combination. If the IOP is markedly elevated, it would not be inappropriate to commence simultaneously with an alpha-agonist, topical nonselective beta blocker, and topical carbonic anhydrase inhibitor.",

author = "Wenick, {Adam S.} and Robin, {Alan L.}",

year = "2010",

doi = "10.1007/978-3-540-68240-0_49",

language = "English (US)",

isbn = "9783540682387",

pages = "379--387",

booktitle = "Pearls of Glaucoma Management",

publisher = "Springer Berlin Heidelberg",

}

TY - CHAP

T1 - Glaucomas

T2 - Neovascular glaucoma

AU - Wenick, Adam S.

AU - Robin, Alan L.

PY - 2010

Y1 - 2010

N2 - Topical and oral medical therapies are the initial treatment of choice to lower intraocular pressure (IOP) and limit vision loss and pain secondary to neovascular glaucoma (NVG). Therapies aimed at decreasing aqueous production (beta-blockers, topical and systemic carbonic anhydrase inhibitors, and alpha adrenergics) have the soundest rationale for use in NVG. No study is available in the literature comparing effectiveness of these various medications in NVG, and they are often required in combination. If the IOP is markedly elevated, it would not be inappropriate to commence simultaneously with an alpha-agonist, topical nonselective beta blocker, and topical carbonic anhydrase inhibitor.

AB - Topical and oral medical therapies are the initial treatment of choice to lower intraocular pressure (IOP) and limit vision loss and pain secondary to neovascular glaucoma (NVG). Therapies aimed at decreasing aqueous production (beta-blockers, topical and systemic carbonic anhydrase inhibitors, and alpha adrenergics) have the soundest rationale for use in NVG. No study is available in the literature comparing effectiveness of these various medications in NVG, and they are often required in combination. If the IOP is markedly elevated, it would not be inappropriate to commence simultaneously with an alpha-agonist, topical nonselective beta blocker, and topical carbonic anhydrase inhibitor.

UR - http://www.scopus.com/inward/record.url?scp=84892006510&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892006510&partnerID=8YFLogxK

U2 - 10.1007/978-3-540-68240-0_49

DO - 10.1007/978-3-540-68240-0_49

M3 - Chapter

AN - SCOPUS:84892006510

SN - 9783540682387

SP - 379

EP - 387

BT - Pearls of Glaucoma Management

PB - Springer Berlin Heidelberg

ER -

Glaucomas: Neovascular glaucoma

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this